Commercial development is a core competency in an early stage company, especially in a resource-constrained environment. The ability to identify potential investors early and align the development plan to meet the expectations of the investors are critical to optimize value and the return on investment (ROI). Understanding the needs, requirements, and opportunities of potential strategic partners is a key step in these transactions.
CSSi LifeSciences™ has the industry experience and knowledge to connect companies to strategic investors and resources that can rapidly accelerate a research discovery to commercialization. We have helped our clients raise over $700M USD of capital over the past three years1.
For a list active clients we are supporting, please visit our Innovation SmartHub™.
SmartConnect™ enables early stage and emerging growth companies to connect with resources and specialized services to expedite technology development and to traverse the "Valley of Death" to drive value and accelerate your research discovery to commercialization.
Commercial support for early technology development is essential to determine the therapeutic areas, indications, or medical procedures that are commercially viable. The design of a competitive Target Product Profile guides both early and late stage development. Understanding the market opportunity and value proposition a technology offers is key to attracting funding or finding a strategic partner. Investing millions of dollars on clinical trials can be devastating if the true commercial potential of an asset in development is not understood early in the process.
We have extensive experience and deep subject matter expertise in all core areas of the commercialization pathway, including new product planning, strategic marketing, portfolio planning, market opportunity and commercial assessments, pre-launch and launch strategy, interaction with Key Opinion Leaders and core message development. In addition, we can provide fund-raising preparation and high-level connections for both non-dilutive and dilutive opportunities.
CSSi LifeSciences provides unbiased assessments of your intellectual property with strategic recommendations for a successful clinical and regulatory pathway to commercialization.
Our scientific and technical review of the data and the product portfolio provides unbiased portfolio assessment. We are uniquely positioned to provide a comprehensive review and “Gap Assessment” of the preclinical, nonclinical, GMP, clinical, and engineering controls to provide investors with a projected budget and timeline.
CSSi LifeSciences provides in-depth technical expertise for the assessment of likelihood of product development, regulatory and commercial success and return on investment.
CSSi LifeSciences works with companies to build an IP Fortress that conforms to your overall business strategy. In conjunction with your IP counsel, our technical experts can assist you in coordinating new IP with your regulatory and business development or partnering strategies.